IL157226A0 - Composition and method for potentiating drugs - Google Patents

Composition and method for potentiating drugs

Info

Publication number
IL157226A0
IL157226A0 IL15722601A IL15722601A IL157226A0 IL 157226 A0 IL157226 A0 IL 157226A0 IL 15722601 A IL15722601 A IL 15722601A IL 15722601 A IL15722601 A IL 15722601A IL 157226 A0 IL157226 A0 IL 157226A0
Authority
IL
Israel
Prior art keywords
composition
potentiating
drug
effective amount
cns
Prior art date
Application number
IL15722601A
Other languages
English (en)
Original Assignee
Gevys Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gevys Pharmaceuticals Ltd filed Critical Gevys Pharmaceuticals Ltd
Publication of IL157226A0 publication Critical patent/IL157226A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15722601A 2001-02-05 2001-12-19 Composition and method for potentiating drugs IL157226A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/775,794 US6833377B2 (en) 2001-02-05 2001-02-05 Composition and method for potentiating drugs
PCT/IB2001/002566 WO2002062388A1 (fr) 2001-02-05 2001-12-19 Composition et methode de potentialistion de medicaments

Publications (1)

Publication Number Publication Date
IL157226A0 true IL157226A0 (en) 2004-02-19

Family

ID=25105521

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15722601A IL157226A0 (en) 2001-02-05 2001-12-19 Composition and method for potentiating drugs
IL157226A IL157226A (en) 2001-02-05 2003-08-04 Composition for potentiating drugs and its preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL157226A IL157226A (en) 2001-02-05 2003-08-04 Composition for potentiating drugs and its preparation

Country Status (11)

Country Link
US (1) US6833377B2 (fr)
EP (1) EP1359939B1 (fr)
AT (1) ATE343399T1 (fr)
AU (1) AU2002219417B2 (fr)
CA (1) CA2437351A1 (fr)
DE (1) DE60124144T2 (fr)
DK (1) DK1359939T3 (fr)
ES (1) ES2275624T3 (fr)
IL (2) IL157226A0 (fr)
PT (1) PT1359939E (fr)
WO (1) WO2002062388A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050192220A1 (en) * 2001-02-05 2005-09-01 Gevys Pharmaceuticas Ltd. Composition and method for potentiating drugs
US9877921B2 (en) 2005-09-09 2018-01-30 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
US20070059361A1 (en) * 2005-09-09 2007-03-15 University Of Manitoba Fast-disintegrating epinephrine tablets for buccal or sublingual administration
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
TW200817049A (en) * 2006-06-05 2008-04-16 Verus Pharmaceuticals Inc Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms
WO2007143675A2 (fr) * 2006-06-05 2007-12-13 Verus Pharmaceuticals, Inc. Procédés pour des posologies buccales, linguales ou sublinguales d'epinéphrine pour le traitement d'urgences allergiques
US20080108970A1 (en) * 2006-11-08 2008-05-08 Viertio-Oja Hanna E Control of Drug Administration
US8729070B2 (en) * 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
CA2716080C (fr) * 2008-02-20 2016-12-13 Targia Pharmaceuticals Compositions pharmaceutiques actives sur le snc et methodes d'utilisation
US20120322884A1 (en) 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP2753321B1 (fr) 2011-10-21 2021-12-15 Nova Southeastern University Nanoparticules d'épinéphrine, leurs procédés de fabrication et leurs procédés d'utilisation pour le traitement d'états sensibles à l'épinéphrine
CA3169368A1 (fr) 2012-06-15 2014-01-09 Nova Southeastern University Nanoparticules d'epinephrine, procede pour les fabriquer et procedes pour les utiliser pour le traitement d'affections repondant a l'epinephrine
DK2976072T3 (da) 2013-03-22 2021-08-16 Univ Nova Southeastern Epinephrinfinpartikler og fremgangsmåder til anvendelse deraf til behandling af tilstande, der reagerer på epinephrin
WO2016027259A1 (fr) * 2014-08-21 2016-02-25 Targia Pharmaceuticals Compositions pharmaceutiques pour le système nerveux central et procédés d'utilisation
CN110325214A (zh) * 2016-12-22 2019-10-11 Rvx疗法有限公司 用于预防和治疗神经元损伤的低剂量药物组合
US20220347122A1 (en) * 2019-03-15 2022-11-03 Ftf Pharma Private Limited Solutions for oral dosage

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947579A (en) 1974-06-03 1976-03-30 Nelson Research & Development Company Method and composition for potentiating neuroleptic drugs
DE3321969A1 (de) 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4843071A (en) 1986-12-05 1989-06-27 Serotonin Industries Of Charleston Method and composition for treating obesity, drug abuse, and narcolepsy
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US5431922A (en) 1991-03-05 1995-07-11 Bristol-Myers Squibb Company Method for administration of buspirone
US5891842A (en) 1993-04-09 1999-04-06 Trustees Of Tufts College Methodology for eliciting an analgesic response in a living subject
CA2134038C (fr) 1994-06-16 1997-06-03 David Taiwai Wong Potentialisation des effets de medicaments
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
EP0714663A3 (fr) 1994-11-28 1997-01-15 Lilly Co Eli Potentialisation d'un médicament par un antagoniste du récepteur sérotonine 1A
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
CA2388593A1 (fr) * 1999-11-12 2001-05-17 Neurogen Corporation Composes heteroaromatiques bicycliques et tricycliques

Also Published As

Publication number Publication date
IL157226A (en) 2010-11-30
DK1359939T3 (da) 2007-02-26
ATE343399T1 (de) 2006-11-15
EP1359939A1 (fr) 2003-11-12
US20030004134A1 (en) 2003-01-02
WO2002062388A1 (fr) 2002-08-15
EP1359939B1 (fr) 2006-10-25
AU2002219417B2 (en) 2007-03-22
DE60124144T2 (de) 2007-09-06
ES2275624T3 (es) 2007-06-16
US6833377B2 (en) 2004-12-21
DE60124144D1 (de) 2006-12-07
CA2437351A1 (fr) 2002-08-15
PT1359939E (pt) 2007-02-28

Similar Documents

Publication Publication Date Title
IL157226A0 (en) Composition and method for potentiating drugs
MXPA02002249A (es) Composiciones farmaceuticas agradables al paladar para animales de compania.
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2002074247A3 (fr) Formulations pharmaceutiques a liberation prolongee
HK1076605A1 (en) Formulations
MXPA03008756A (es) Derivados de n-(arilsulfonil) beta-aminoacidos que comprenden un grupo aminometilo substituido, el metodo de preparacion de los mismos y las composiciones farmaceuticas que los contienen.
WO2005032474A3 (fr) Compositions pharmaceutiques pour prevenir une dose excessive ou un abus
WO2004043377A3 (fr) Procedes et compositions utilisant des composes immunomodulateurs pour traiter et maitriser des cancers et d'autres maladies
TW200510375A (en) New compounds
TNSN08140A1 (fr)
NO962841D0 (no) Anvendelse av 2-hydroksy-5-fenylazobenzosyrederivater som colon cancer kjemopreventativer og kjemoterapeutiske midler
WO2005117895A3 (fr) Compositions contenant de la meloxicame
WO2003045306A3 (fr) Composes phenoxy amine et compositions pour administrer des principes actifs
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
WO2010053861A3 (fr) Amides biologiquement actifs
WO2001000617A3 (fr) Nouveaux derives de piperazinyl-alkyl-thiopyrimidine compositions pharmaceutiques les contenant et procede de preparation de la substance active
WO2003035080A3 (fr) Procede de preparation de compositions pharmaceutiques servant a administrer localement des inhibiteurs de l'enzyme cyclooxygenase-2
WO2007011958A3 (fr) Formes posologiques intra-buccales de glucagon
PL377683A1 (pl) System terapeutyczny zawierający amoksycylinę i kwas klawulanowy
WO2004087880A8 (fr) Composes et leur utilisation dans le traitement du diabete et troubles connexes
IL162860A0 (en) Sedative non-benzodiazepine formulations
WO2004062564A3 (fr) Formulations non-benzodiazepine sedatives
MXPA05010707A (es) Combinaciones que comprenden farmacos anti-epilepticos para el tratamiento de desordenes neurologicos.
WO2005004878A3 (fr) Recipients a multi-usage pour formulations de vitamine d
WO2005062874A3 (fr) Composes et compositions pour l'administration d'agents actifs